The prevalence of house dust mite (HDM) sensitisation is high [1, 2] and represents a significant risk factor in the development of respiratory allergic disease [3‐5]. Therefore, we conducted a multicentre, epidemiological, ambispective, cross-sectional study to determine the clinical characteristics of patients with HDM-induced respiratory allergic disease in Spain, along with their quality of life (QoL). A secondary objective was to assess the extent of asthma control during the year prior to inclusion in the study. Patients (aged 14–55 years) from 33 clinical groups working in Spain were eligible to participate if they had respiratory allergic disease (rhinitis or rhinitis and asthma with/without conjunctivitis) for at least 2 years that was due to HDM, had a positive skin prick test (wheal diameter ≥ 3 mm) and/or were immunoglobulin E positive (class 2 or above), as measured by ImmunoCAP (Thermofisher, Uppsala, Sweden), and who had not received immunotherapy in the 5 years prior to their inclusion in the study. The patients were included between October 2015 and February 2017, and gave written consent to participate in the study.
Rhinitis was assessed according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines [6] and asthma was assessed according to the Spanish Guideline on the Management of Asthma (GEMA) [7] and the Asthma Control Questionnaire (ACQ, Spanish adult version for all patients). Quality of life in patients with asthma was assessed by the mini version of the Asthma Questionnaire on Quality of Life (miniAQLQ). For rhinoconjunctivitis, QoL was determined using the mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ) and the ESPRINT-15 [8]. Patients were asked about medication used for the symptomatic treatment of respiratory allergic disease caused by HDM in the year prior to their inclusion in the study. All information was collected during a single visit.
Anzeige
Overall, 296 patients (mean age of 29.5 ± 10.0 years) were evaluated (Table 1). Most patients (n = 179; 60.5%) had rhinitis without asthma and 117 patients (39.5%) had rhinitis with asthma. Almost all patients (98.7%) were sensitised to Dermatophagoides pteronyssinus and 78.3% of patients were sensitised to D. farinae. With respect to storage mites, 48.5% of patients tested positive for sensitivity to Lepidoglyphus, 31.5% for Tyrophagus, 20.3% for Glycyphagus and 15.5% for Blomia.
Table 1
Baseline characteristics
Patients with rhinitis (without asthma) | Patients with rhinitis (with asthma) | |||
|---|---|---|---|---|
n | % | n | % | |
Age group | ||||
Adolescents (14–17 years) | 20 | 11.2 | 16 | 13.7 |
Adults (18–55 years) | 158 | 88.3 | 101 | 86.3 |
Gender | ||||
Female | 94 | 52.8 | 77 | 65.8 |
Male | 84 | 47.2 | 40 | 34.2 |
Conjunctivitis | ||||
Yes | 114 | 64.4 | 74 | 63.3 |
Rhinitis | ||||
Intermittent | 40 | 22.6 | 27 | 24.3 |
Persistent | 137 | 77.4 | 84 | 75.7 |
Mild | 48 | 27.1 | 29 | 25.7 |
Moderate-to-Severe | 129 | 72.9 | 84 | 74.3 |
Asthma | ||||
Intermittent | 47 | 41.2 | ||
Mild persistent | 45 | 39.5 | ||
Moderate persistent | 20 | 17.5 | ||
Severe persistent | 2 | 1.8 | ||
In the year prior to inclusion, 58.8% of patients used allergen avoidance measures; 10.3% of patients visited the emergency room due to their allergy. More patients with asthma (20.7%) than with rhinitis (3.4%) had an emergency room visit because of their respiratory allergic disease in the year prior to inclusion. Only one patient required hospitalisation due to asthma during this period prior to inclusion.
The ESPRINT-15 questionnaire was used to evaluate the overall QoL in patients with rhinoconjunctivitis, as well as specific domains including Symptoms, Daily life activities, Sleep, Psychological effects and General state of health (Table 2). No statistically significant differences were seen among patients with rhinitis and asthma compared with those who had rhinitis alone (with/without conjunctivitis). There was a significant difference between adolescents and adults in the domains of sleep, psychological effects, general state of health and overall QoL, with a greater impact in the adult population (Table 2).
Table 2
Results of the Quality of Life Questionnaires
Overall | Adolescents | Adults | |
|---|---|---|---|
ESPRINT-15 Quality of Life Questionnaire | |||
Symptoms (items 1–5) | |||
Mean (SD) | 3.03 (1.41) | 2.62 (1.45) | 3.09 (1.40) |
Median [Q1, Q3] | 3.00 [2.00, 4.00] | 2.20 [1.50, 3.90] | 3.20 [2.00, 4.20] |
0.0635 | |||
Daily life activities (items 6–8) | |||
Mean (SD) | 2.23 (1.56) | 1.85 (1.30) | 2.28 (1.59) |
Median [Q1, Q3] | 2.33 [1.00, 3.33] | 2.00 [0.67, 3.00] | 2.33 [1.00, 3.33] |
0.1978 | |||
Sleep (items 9–11) | |||
Mean (SD) | 2.29 (1.83) | 1.71 (1.72) | 2.38 (1.84) |
Median [Q1, Q3] | 2.00 [0.67, 3.67] | 1.33 [0.17, 2.83] | 2.00 [0.67, 3.67] |
0.0338 | |||
Psychological effects (items 12–14) | |||
Mean (SD) | 2.38 (1.70) | 1.82 (1.52) | 2.47 (1.72) |
Median [Q1, Q3] | 2.33 [1.00, 3.67] | 1.67 [0.50, 2.83] | 2.33 [1.00, 3.67] |
0.0381 | |||
General State of Health (item 15) | |||
Mean (SD) | 3.08 (0.94) | 2.72 (1.06) | 3.13 (0.91) |
Median [Q1, Q3] | 3.00 [2.00, 4.00] | 3.00 [2.00, 3.50] | 3.00 [3.00, 4.00] |
0.0323 | |||
Overall (items 1–15) | |||
Mean (SD) | 2.57 (1.33) | 2.13 (1.22) | 2.63 (1.34) |
Median [Q1, Q3] | 2.53 [1.47, 3.47] | 2.10 [1.23, 2.77] | 2.60 [1.53, 3.53] |
0.0365 | |||
MiniRQLQ Questionnaire | |||
Activities (items 1–3) | |||
Mean (SD) | 2.66 (1.43) | 1.94 (1.28) | 2.76 (1.42) |
Median [Q1, Q3] | 2.67 [1.67, 3.67] | 1.67 [1.00, 2.67] | 2.67 [1.83, 3.67] |
0.0014 | |||
Practical problems (items 4–5) | |||
Mean (SD) | 3.77 (1.61) | 3.42 (1.71) | 3.82 (1.60) |
Median [Q1, Q3] | 4.00 [2.50, 5.00] | 3.50 [2.00, 4.75] | 4.00 [2.50, 5.00] |
0.1730 | |||
Nasal symptoms (items 6–8) | |||
Mean (SD) | 3.54 (1.48) | 3.24 (1.55) | 3.58 (1.47) |
Median [Q1, Q3] | 3.67 [2.67, 4.67] | 3.33 [2.00, 4.00] | 3.67 [2.67, 4.67] |
0.1988 | |||
Ocular symptoms (items 9–11) | |||
Mean (SD) | 2.15 (1.74) | 1.81 (1.71) | 2.20 (1.74) |
Median [Q1, Q3] | 2.00 [0.67, 3.33] | 1.33 [0.17, 3.67] | 2.00 [0.67, 3.33] |
0.2071 | |||
Other symptoms (item 12–14) | |||
Mean (SD) | 1.56 (1.71) | 1.56 (1.71) | 2.13 (1.59) |
Median [Q1, Q3] | 2.00 [0.67, 3.33] | 1.00 [0.17, 2.33] | 2.00 [0.67, 3.33] |
0.0242 | |||
Overall (items 1–14) | |||
Mean (SD) | 2.76 (1.29) | 2.32 (1.32) | 2.83 (1.28) |
Median [Q1, Q3] | 2.71 [1.79, 3.64] | 2.00 [1.25, 3.57] | 2.71 [1.86, 3.64] |
0.0386 | |||
There was a significant difference in the miniRQLQ scores between adolescents and adults in the activities domain, in other symptoms and in the overall score (Table 2). There were no differences between patients who had asthma in addition to rhinitis compared with those who only had rhinitis (with/without conjunctivitis). Asthma was associated with a lower impact on QoL compared with rhinitis (medians of different domains: 4.7–5.8), with no statistically significant differences recorded between adolescents and adults. Patients had varying degrees of asthma control at baseline, as determined using ACQ scores: 45.2% of patients scored > 1.5 (inadequate control of the disease), 34.5% had adequate control (score < 0.75) and the remaining 20.2% had partially controlled asthma (0.75–1.5).
Anzeige
Having persistent severe asthma with additional conjunctivitis were the factors significantly associated with a worse result in the ACQ (higher score), in both the linear and the logistic model. Factors which reduced QoL in patients with rhinitis as measured by ESPRINT-15 and miniRQLQ included persistent, moderate-to-severe rhinitis with additional conjunctivitis and being female. For patients with asthma, adequately controlled asthma and absence of concurrent conjunctivitis were associated with improved quality of life.
This cross-sectional study of patients allergic to HDM in Spain indicates that respiratory allergic disease due to HDM has a moderate impact on patient QoL and this impact is influenced more by the presence of rhinitis than asthma. In some studies, sleep and daily activities were the QoL domains most affected in patients allergic to HDM [9, 10], but the current study found no differences between the different domains of rhinitis questionnaires. Several non-specific triggers can influence the severity of symptoms of respiratory allergic diseases, including changes in temperature, air pollution and cigarette smoke [11]. Variation in these factors could have been responsible for the differences in results between the present and previous studies. In the present study, differences between adults and adolescents were found in different domains of ESPRINT-15 and miniRLQL, indicating that both questionnaires provide complementary information.
Notwithstanding the limitations inherent in a cross-sectional study design, this study shows that Spanish patients with allergic asthma and/or rhinitis due to HDM have moderately reduced QoL, which is significantly influenced by rhinitis, despite continuous treatment. Age is a determining factor in QoL in this population, and its impact is more negative in adults than in adolescents.
These findings highlight the importance of effective management of upper airway symptoms in patients with respiratory allergic disease.
Acknowledgements
This study would not be possible without the contribution of all the investigators of the EpidMite study, listed as follows in alphabetical order: Aldunate María Teresa, H. Reina Sofía (Navarra, Spain); Álvarez José Antonio, C.P. Oviedo (Asturias, Spain); Añó Miguel, Alergocantabria (Santander, Spain); Campos Gonzalo, H. Internacional Xanit (Málaga, Spain); Cardona Victoria, HU Vall D’Hebrón & ARADyAL research network (Barcelona, Spain); Cruz Sergia, CH Torrecárdenas (Almería, Spain); De Luque Virginia, HU Virgen Macarena (Seville, Spain); Fernández Agustín, H NISA Virgen del Consuelo (Valencia); Figueroa Javier, HU Insular Gran Canaria (Las Palmas, Spain); Gaig Pere, HU Joan XXIII (Tarragona, Spain); Gómez Belén, H. Reina Sofía (Navarra, Spain); González Genoveva, Amb. Deusto (Vizcaya, Spain); Gutiérrez Diego, H Puerta del Mar (Cádiz, Spain); Iglesias Javier, H Sur (Sta Cruz de Tenerife); Jover Vicente, Rodríguez-Pacheco Ramón, Domenech Joan, HGU Elda (Alicante, Spain); Kraemer Raquel, Clínica Juaneda (Palma de Mallorca); Linares Tania, Escudero Elena, Rodríguez-Zuazo Idoia, HP Pontevedra (Pontevedra, Spain); López Damián, Sánchez-Guerrero Inmaculada HCU Virgen de Arrixaca (Murcia, Spain); Llamas Estrella, HG Granollers (Barcelona, Spain); Malet Alfons, Clínica Teknon (Barcelona, Spain); Maraví Antonio, Clínica Milenium (Seville, Spain); Martín-Lázaro Joaquín, HU Lucus Augusti (Lugo, Spain); Molina Montserrat, HG Hospitalet (Barcelona, Spain); Montoro Javier, H. Arnau de Vilanova (Valencia, Spain); Moreno Carmen, CH Torrecárdenas (Almería, Spain); Moya Carmen, CH Torrecárdenas (Almería, Spain); Pamies Rafael, H. Dr Gálvez (Málaga, Spain); Pérez-Pastor Laura, H. Viamed (Seville, Spain); Quiñones Dolores, H. Monte Naranco (Asturias, Spain); Raducán Isabella, Clínica TECMA (Valencia, Spain); Rodríguez Fernando, HU Marqués de Valdecilla (Santander, Spain); Rueda María, H. Quirón (Barcelona, Spain); Sánchez Cesárea, H. Juan Ramón Jiménez – UGC Neumología Alergia (Huelva, Spain); Sánchez-Machín Inmaculada, H. Tórax (Tenerife, Spain); Vidal Carmen, López Freire Sara, CHU Santiago (A Coruña, Spain); Zapata Juan José, Clínica de Alergia Dr. Juan J Zapata (Almería, Spain).
This article does not contain any studies with human participants performed by any of the authors, so no approval from an institutional review board was required for the production of this manuscript.
Ethics approval and consent to participate
All patients gave written consent to take part in the study and the study was approved by the health authorities. The Ethical Committee of the Hospital Central de Asturias was the committee of reference.
Consent for publication
Not applicable.
Anzeige
Competing interests
A Beristain: no competing interest. Fernando de la Torre is an employee of ALK-Abelló, S.A., Madrid, Spain.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.